Stock chart
Analyses on NUR INK (4)
- March 18, 2026March 18, 2026
- Follow-up
Nur Ink: What the DCC Agreement Is Really Worth, and Who Captures the Value If It Works
The DCC agreement is larger than a plain distribution contract because it combines ink supply, exclusivity, royalties, and an equity option, but the value to Nur is not additive: the cleaner value sits in product sales and royalties, while the upside from up to 20% of the distri…
- Follow-up
Nur Ink: The Warrants and Shareholder Support, How Much Time Does the Financing Bridge Really Buy
Nur Ink’s financing bridge is real, but shorter than the warrant headlines suggest: on the 2025 cash-burn reference, cash at report date plus the committed 10/24 exercises buys less than eight months of activity, and only the shareholder backstop pushes the company beyond the on…
- Follow-up
Nur Ink: The Development Asset Is 35x Revenue, When Does It Start Working
Nur Ink’s 2025 loss looks slightly better on the surface, but the business economics still rely on capitalized development and external funding: the intangible asset rose to NIS 11.428 million, almost 35x revenue, while sales and gross margin still do not validate that carrying…
Nur Ink in 2025: The Commercial Door Is Open, but the Balance Sheet Is Still Buying Time
Nur Ink entered 2026 with its first real pieces of commercial proof, but the economics of the story are still driven more by financing pace and conversion of development into sales than by operating profitability.
